The efficiency of this new method in curing cancer based on two things the size of the tumor and its convenience to the probes. Generally, for cancers 3 cm or less and easily used percutaneously the focus is to totally kill the malignancy. The larger the cancer the more problematic it is to gain contest cancer fatality, hence early therapy is vital.
Continuous increase in geriatric population is rising the financial burden on the healthcare system. As per Population Reference Bureau, the count of people in the U.S. aged 65 and above is assessed to approximately double from 52 million in 2018 to 95 million by 2060. Such increase in elderly population will consequently lead in greater need for ablation devices for therapy of tumor, fueling the market
On contrary, for introduced tools sold in the U.S., FDA’s Center for Devices and Radiological Health controls the framework and standards about production, labeling, packaging, and storage. To receive grants and permissions, the organizations require to comply with an exhaustive list of standards offered by official regulatory and keep complete documentation of the similar things.
- This report provides in-depth analysis of the global tumor ablation market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2028), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global tumor ablation market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Major players in the global tumor ablation therapy market are Medtronic, Johnson & Johnson Services Inc., Boston Scientific Corporation, IceCure Medical, EDAP TMS, Theraclion, H.S. Hospital Service SPA and AngioDyna mics.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global tumor ablation market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global tumor ablation market
-
- Radiofrequency Ablation
- Microwave Ablation
- Cryo Ablation
- Irreversible Electroporation
- Laser Based Thermal Ablation
- Other Ablation Technologies
-
- Surgical Ablation
- Laparoscopic Ablation
- Percutaneous Ablation
-
- Kidney Cancers
- Liver Cancers
- Breast Cancers
- Lung Cancers
- Prostate Cancers
- Colorectal Cancers
- Other Cancers
-
- North America
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
-
- Medtronic
- Johnson & Johnson Services Inc.
- Boston Scientific Corporation
- IceCure Medical
- EDAP TMS
- Theraclion
- H.S. Hospital Service SPA
- AngioDynamics
